Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.
The study, which is being conducted under an FDA-approved protocol, is evaluating the treatment in patients suffering from Alcohol Use Disorder (AUD).
The clinical update, released on April 20, 2026, highlighted data from the third and final dose-escalation cohort.
Results demonstrated a high safety profile and favorable overall tolerability.
Notably, investigators reported no serious adverse events (SAEs) across the study population, including those administered the highest dose tested in the escalation protocol.
CMND-100 is an oral therapy based on MEAI (5-methoxy-2-aminoindane), a non-hallucinogenic compound that targets the neural pathways associated with addictive behavior.
By regulating dopamine levels and interacting with the serotonin system, MEAI is designed to reduce the "craving" for alcohol and the impulse to consume it, without the psychoactive or hallucinogenic side effects typically associated with traditional psychedelic treatments.
Alcohol Use Disorder remains a significant global health challenge with limited effective pharmacological interventions.
Clearmind’s approach seeks to address the high unmet medical need by providing a patient-administered, non-invasive oral option that can be integrated into standard outpatient care.
Following the successful completion of the dose-escalation phase, Clearmind plans to move forward with further clinical advancement, focusing on characterizing the efficacy and optimal dosing regimen of CMND-100.